• If you are wondering whether Hinge Health at around US$44.60 is priced for opportunity or already reflects high expectations, the next sections will walk through what the current share price may be implying.
• The stock has recently shown mixed momentum, with a 3.1% move over the last 7 days, a 15.7% change over 30 days, and a year to date return of a 2.1% decline.
• Recent headlines have focused on Hinge Health's role in digital musculoskeletal care and its position within the broader healthcare technology space, which can influence how investors think about growth and risk. This context helps explain why sentiment around the stock has been shifting over the past few weeks.
• Hinge Health currently holds a value score of 3 out of 6. The rest of this article will break down how different valuation methods arrive at that view, and will also point to a more complete way to think about value at the end.

Approach 1: Hinge Health Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting its future cash flows and then discounting them back to today’s value.

For Hinge Health, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $164.8 million. Analysts and extrapolations point to free cash flow reaching $446.0 million in 2030, with interim projections between 2026 and 2035 ranging from $213.5 million to $629.4 million, all in dollar terms and adjusted for time value in the model.

Bringing those cash flows back to today gives an estimated intrinsic value of about $157.97 per share. Compared with a current share price of around $44.60, the model implies an intrinsic discount of roughly 71.8%, which suggests the shares are currently priced well below this cash flow based estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Hinge Health is undervalued by 71.8%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Hinge Health Price vs Sales

For companies where earnings are not the cleanest guide, the P/S ratio often gives a clearer read on how the market values each dollar of revenue. It is especially useful when profits are limited or volatile, because sales are usually more stable than earnings.

In general, higher expected growth and lower business risk tend to justify a higher “normal” P/S multiple, while slower growth and higher uncertainty usually line up with a lower one. So, you want to compare the current P/S both to peers and to what would be reasonable given the company’s own profile.

Hinge Health currently trades at a P/S of 5.87x. That sits above the Healthcare industry average P/S of 1.21x and also above the peer group average of 4.49x. Simply Wall St’s Fair Ratio framework estimates what a more tailored P/S might look like, at 5.46x, using inputs such as earnings growth, profit margins, industry, market cap and risk profile. Because it is built on company specific drivers rather than simple comparisons, the Fair Ratio can be a more precise anchor than broad industry or peer averages alone. On this basis, Hinge Health’s actual P/S of 5.87x is modestly above the Fair Ratio of 5.46x, which indicates that the shares look slightly expensive on this metric.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Hinge Health Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives on Simply Wall St give you a clear story behind the numbers by tying your view of Hinge Health’s business to specific assumptions for future revenue, earnings and margins. This links that forecast to a Fair Value that you can compare with the current price and updates automatically as new news or earnings arrive. This helps explain why some investors might lean toward a higher Fair Value around US$72.0 while others sit closer to US$43.4 when they look at the same company on the Community page.

For Hinge Health however we will make it really easy for you with previews of two leading Hinge Health Narratives:

Fair Value: US$72.00

Implied discount to this Fair Value: 38.1%

Revenue growth assumption: 24.3%

• Backs a view that Hinge Health can keep expanding its musculoskeletal platform across 24.6 million contracted lives and thousands of large employer and health plan clients.
• Relies on AI driven care tools and the Robin assistant to support high engagement, strong gross margins and operating margin around 20% with free cash flow margin around 31%.
• Assumes revenue reaches about US$1.1b by 2029, earnings of US$177.7m and a future P/E of 47.9x that supports a Fair Value of US$72.00 when discounted at roughly 7%.

Fair Value: US$43.40

Implied premium to this Fair Value: 2.8%

Revenue growth assumption: 16.9%

• Highlights that future revenue still depends on converting more of roughly 25 million contracted lives in a market where employer benefit budgets and plan designs can limit adoption.
• Questions how much further AI and workflow efficiency can push margins after early gains and notes that HingeSelect and new programs may require years of investment before contributing meaningfully to revenue.
• Assumes revenue of US$939.3m and earnings of US$125.4m by 2029, with a 41.3x P/E leading to a Fair Value of US$43.40 when discounted at about 7%.

If you want to see how your own assumptions compare with these bullish and bearish setups, and how the wider community frames Hinge Health's potential, take a closer look at the full set of narratives, including the community views and detailed valuation links, on Simply Wall St, starting with the See what the community is saying about Hinge Health.

Do you think there's more to the story for Hinge Health? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.